PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting ...

See rules for symposium and poster presentations regarding the situation from Instructions tab ... with relevance both for healthy brain functioning and for neurological and neuropsychiatric disorders ...

(Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer’s disease ("Alzheimer’s"), bipolar disorder ("BD"), major ...